申请人:MONTE ROSA THERAPEUTICS AG
公开号:WO2022219407A1
公开(公告)日:2022-10-20
Disclosed herein are compound or pharmaceutically acceptable salts or stereoisomers thereof of Formula (I), wherein X1is selected from the group consisting of linear or branched C1-6alkyl, C3-6cycloalkyl, C6-10aryl, 5-10 membered heteroaryl, and 4-8 membered heterocycloalkyl, wherein X1is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, linear or branched C1-6alkyl, linear or branched C1-6heteroalkyl, CF3, CHF2, CMeF2, -O-CHF2, -O-(CH2)2-OMe, OCF3, C1-6alkylamino, -CN, NH2, C1-4alkoxy and C1-4alkylhydroxy; X2is selected from the group consisting of H, C3-6cycloalkyl, C6-10aryl, 5-10 membered heteroaryl, and 4-8 membered heterocycloalkyl, wherein X2is unsubstituted or substituted with one or more substituents independently selected from the group consisting of linear or branched C1-6alkyl, -C1-4alkoxy, NH2, NMe2, halogen, CF3, CHF2, CMeF2, -O-(CH2)2-OMe, OCF3, OCHF2, and C1-4alkylhydroxy; Y is selected from the group consisting of linear or branched C1-6alkyl, -C1-4alkoxy, -CN, halogen, CF3,CHF2, CMeF2, OCF3, and OCHF2; L1is linear or branched C1-6alkyl; L2is selected from a covalent bond, and linear or branched C1-6alkyl; and L3is selected from the group consisting of a covalent bond, linear or branched C1-6alkyl, -O-, and -C1-4alkoxy. Disclosed herein is also their use as modulators of cereblon, methods of preparation of these compounds, compositions comprising these compounds, and methods of using them in the treatment of abnormal cell growth in mammals, especially humans.
本文披露了式(I)的化合物或药学上可接受的盐或其立体异构体,其中X1选自线性或支链C1-6烷基,C3-6环烷基,C6-10芳基,5-10成员杂芳基和4-8成员杂环烷基的群,其中X1未取代或取代有一个或多个取代基,独立地选自卤素,线性或支链C1-6烷基,线性或支链C1-6杂烷基,CF3,CHF2,CMeF2,-O-CHF2,-O-(CH2)2-OMe,OCF3,C1-6烷基氨基,-CN,NH2,C1-4烷氧基和C1-4烷基羟基;X2选自H,C3-6环烷基,C6-10芳基,5-10成员杂芳基和4-8成员杂环烷基的群,其中X2未取代或取代有一个或多个取代基,独立地选自线性或支链C1-6烷基,-C1-4烷氧基,NH2,NMe2,卤素,CF3,CHF2,CMeF2,-O-(CH2)2-OMe,OCF3,OCHF2和C1-4烷基羟基;Y选自线性或支链C1-6烷基,-C1-4烷氧基,-CN,卤素,CF3,CHF2,CMeF2,OCF3和OCHF2的群;L1为线性或支链C1-6烷基;L2选自共价键和线性或支链C1-6烷基;L3选自共价键,线性或支链C1-6烷基,-O-和-C1-4烷氧基的群。本文还披露了它们作为小脑蛋白调节剂的用途,这些化合物的制备方法,包含这些化合物的组合物以及在哺乳动物,特别是人类的异常细胞生长治疗中使用它们的方法。